MA32781B1 - Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine - Google Patents
Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressineInfo
- Publication number
- MA32781B1 MA32781B1 MA33827A MA33827A MA32781B1 MA 32781 B1 MA32781 B1 MA 32781B1 MA 33827 A MA33827 A MA 33827A MA 33827 A MA33827 A MA 33827A MA 32781 B1 MA32781 B1 MA 32781B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- arylcyclohexyl
- concerns
- ether derivatives
- dihydrotetrazapenzoazole
- Prior art date
Links
- 102000004136 Vasopressin Receptors Human genes 0.000 title 1
- 108090000643 Vasopressin Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- VWIXROWPCIMRKG-UHFFFAOYSA-N 5,6-dihydro-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine Chemical compound C1NCC2=CC=CC=C2N2C=NN=C12 VWIXROWPCIMRKG-UHFFFAOYSA-N 0.000 abstract 1
- 206010001488 Aggression Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 abstract 1
- 102000002852 Vasopressins Human genes 0.000 abstract 1
- 108010004977 Vasopressins Proteins 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000012761 aggressive behavior Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960003726 vasopressin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES DÉRIVÉS DE TYPE ARYLCYCLOHEXYLÉTHER DE DIHYDROTÉTRAZABENZOAZULÈNE, PLUS PRÉCISÉMENT DES DÉRIVÉS DE TYPE ARYLCYCLOHEXYLÉTHERS DE 5,6-DIHYDRO-4H-2,3,5,10B-TÉTRAZA-BENZO[E]AZULÈNE DE FORMULE (I) OÙ R1, R2 ET R3 SONT TELS QUE DÉCRITS DANS LA PRÉSENTE INVENTION. LES COMPOSÉS SELON L'INVENTION AGISSENT EN TANT QUE MODULATEURS DES RÉCEPTEURS V1A, ET EN PARTICULIER EN TANT QU'ANTAGONISTES DES RÉCEPTEURS V1A. LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT LEUR FABRICATION, LES COMPOSITIONS PHARMACEUTIQUES LES INCLUANT ET LEUR EMPLOI EN TANT QUE MÉDICAMENT. LES PRINCIPES ACTIFS SELON L'INVENTION PEUVENT ÊTRE EMPLOYÉS EN TANT QUE PRODUITS THÉRAPEUTIQUES À ACTION PÉRIPHÉRIQUE OU CENTRALE DANS LES ÉTATS DE DYSMÉNORRHÉE, DE DYSFONCTIONNEMENT SEXUEL CHEZ L'HOMME OU LA FEMME, D'HYPERTENSION, D'INSUFFISANCE CARDIAQUE CHRONIQUE, DE SÉCRÉTION INADAPTÉE DE VASOPRESSINE, DE CIRRHOSE DU FOIE, DE SYNDROME NÉPHROTIQUE, D'ANXIÉTÉ, DE TROUBLES DÉPRESSIFS, DE TROUBLES OBSESSIONNELS COMPULSIFS, DE TROUBLES DU SPECTRE AUTISTIQUE, DE SCHIZOPHRÉNIE ET DE COMPORTEMENT AGRESSIF.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08170188 | 2008-11-28 | ||
| PCT/EP2009/065354 WO2010060836A1 (fr) | 2008-11-28 | 2009-11-18 | Arylcyclohexyléthers de dihydrotétrazabenzoazulènes pour emploi en tant qu'antagonistes du récepteur v1a de la vasopressine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32781B1 true MA32781B1 (fr) | 2011-11-01 |
Family
ID=41382009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33827A MA32781B1 (fr) | 2008-11-28 | 2011-05-10 | Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8227458B2 (fr) |
| EP (1) | EP2370441B1 (fr) |
| JP (1) | JP5452608B2 (fr) |
| KR (1) | KR101359742B1 (fr) |
| CN (1) | CN102227428B (fr) |
| AR (2) | AR074409A1 (fr) |
| AU (1) | AU2009319123B2 (fr) |
| BR (1) | BRPI0922303B1 (fr) |
| CA (1) | CA2743976C (fr) |
| CO (1) | CO6341478A2 (fr) |
| CR (1) | CR20110220A (fr) |
| CY (1) | CY1115435T1 (fr) |
| DK (1) | DK2370441T3 (fr) |
| EC (1) | ECSP11011089A (fr) |
| ES (1) | ES2431279T3 (fr) |
| HR (1) | HRP20131067T1 (fr) |
| IL (1) | IL212122A (fr) |
| MA (1) | MA32781B1 (fr) |
| MX (1) | MX2011005596A (fr) |
| MY (1) | MY150837A (fr) |
| NZ (1) | NZ592076A (fr) |
| PE (1) | PE20110582A1 (fr) |
| PL (1) | PL2370441T3 (fr) |
| PT (1) | PT2370441E (fr) |
| RU (1) | RU2507205C2 (fr) |
| SG (1) | SG171846A1 (fr) |
| SI (1) | SI2370441T1 (fr) |
| TW (1) | TWI379833B (fr) |
| UA (1) | UA103504C2 (fr) |
| WO (1) | WO2010060836A1 (fr) |
| ZA (1) | ZA201103419B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2799020A1 (fr) | 2010-05-13 | 2011-11-17 | Jennifer R. Allen | Composes d'heteroaryloxycarbocyclyle convenant comme inhibiteurs de la pde10 |
| US8828989B2 (en) * | 2011-09-26 | 2014-09-09 | Hoffmann-La Roche Inc. | Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists |
| EP2763997B1 (fr) * | 2011-10-05 | 2017-08-02 | F. Hoffmann-La Roche AG | Cyclohexyl-4h,6h-5-oxa-2,3,10b-triazabenzo[e]azulènes utilisés comme antagonistes des v1a |
| MX2016001940A (es) * | 2013-08-19 | 2016-06-02 | Hoffmann La Roche | Antagonistas de v1a para tratar trastornos del sueño por cambio de fase. |
| NZ720340A (en) * | 2013-12-05 | 2020-03-27 | Hoffmann La Roche | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof |
| WO2017191117A1 (fr) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Antagonistes du récepteur v1a destinés à une utilisation dans le traitement de maladies rénales |
| RU2666598C1 (ru) * | 2017-07-14 | 2018-09-11 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Средство для коррекции расстройств аутистического спектра |
| US11033601B2 (en) | 2017-09-14 | 2021-06-15 | The Regents Of The University Of Colorado, A Body Corporate | Selective inhibition of V1b for treating fatty liver |
| EP3720424B1 (fr) * | 2017-12-08 | 2022-09-21 | F. Hoffmann-La Roche AG | Formulation pharmaceutique |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| WO2020139670A1 (fr) | 2018-12-27 | 2020-07-02 | Teva Pharmaceuticals International Gmbh | Formes à l'état solide de balovaptan |
| JP2023534713A (ja) * | 2020-07-23 | 2023-08-10 | エフ． ホフマン－ラ ロシュ アーゲー | バソプレシン受容体ｖ１ａアンタゴニストとしてのシクロヘキシル置換トリアゾール |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
| UA70984C2 (uk) | 1999-01-19 | 2004-11-15 | Орто-Макнейл Фармасьютікел, Інк. | Трициклічні бензодіазепіни як антагоністи вазопресинових рецепторів |
| TWI239333B (en) * | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| US7022699B2 (en) | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| GB0303852D0 (en) | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| GB0400700D0 (en) * | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| KR100840852B1 (ko) | 2004-05-25 | 2008-06-23 | 화이자 프로덕츠 인크. | 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체 |
| EP1753766A1 (fr) | 2004-05-25 | 2007-02-21 | Pfizer Products Inc. | Derives de tetraazabenzo(e)azulene et analogues de ceux-ci |
| EP1632494A1 (fr) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Antagonistes de la v1a vasopressine |
| BRPI0514458A (pt) * | 2004-08-25 | 2008-06-10 | Pfizer | triazolbenzodiazepinas e seu uso como antagonistas de vasopressina |
| CA2605899C (fr) | 2005-04-26 | 2011-02-08 | Pfizer Limited | Derives de triazole utilises comme antagonistes de la vasopressine |
| US20080234252A1 (en) | 2005-05-18 | 2008-09-25 | Pfizer Inc | Compounds Useful in Therapy |
| ES2376378T3 (es) | 2007-01-12 | 2012-03-13 | F. Hoffmann-La Roche Ag | Derivados de espiropiperidina-glicinamida. |
| WO2009125800A1 (fr) * | 2008-04-09 | 2009-10-15 | 株式会社クラレ | Stratifié possédant des propriétés de barrière aux gaz et procédé de fabrication associé |
| HRP20121060T1 (hr) | 2008-11-13 | 2013-01-31 | F. Hoffmann - La Roche Ag | Spiro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleni |
| SI2358714T1 (sl) * | 2008-11-18 | 2012-11-30 | Hoffmann La Roche | Alkilcikloheksiletri dihidrotetraazabenzoazulenov |
| US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8492376B2 (en) | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8481528B2 (en) | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
-
2009
- 2009-11-18 EP EP09752380.7A patent/EP2370441B1/fr active Active
- 2009-11-18 ES ES09752380T patent/ES2431279T3/es active Active
- 2009-11-18 CN CN200980147825.3A patent/CN102227428B/zh active Active
- 2009-11-18 RU RU2011123703/04A patent/RU2507205C2/ru active
- 2009-11-18 PT PT97523807T patent/PT2370441E/pt unknown
- 2009-11-18 MX MX2011005596A patent/MX2011005596A/es active IP Right Grant
- 2009-11-18 SI SI200930769T patent/SI2370441T1/sl unknown
- 2009-11-18 MY MYPI20112399 patent/MY150837A/en unknown
- 2009-11-18 NZ NZ592076A patent/NZ592076A/en unknown
- 2009-11-18 BR BRPI0922303-7A patent/BRPI0922303B1/pt active IP Right Grant
- 2009-11-18 UA UAA201107950A patent/UA103504C2/ru unknown
- 2009-11-18 WO PCT/EP2009/065354 patent/WO2010060836A1/fr not_active Ceased
- 2009-11-18 SG SG2011038692A patent/SG171846A1/en unknown
- 2009-11-18 AU AU2009319123A patent/AU2009319123B2/en active Active
- 2009-11-18 JP JP2011537933A patent/JP5452608B2/ja active Active
- 2009-11-18 PL PL09752380T patent/PL2370441T3/pl unknown
- 2009-11-18 PE PE2011001019A patent/PE20110582A1/es active IP Right Grant
- 2009-11-18 HR HRP20131067AT patent/HRP20131067T1/hr unknown
- 2009-11-18 KR KR1020117012049A patent/KR101359742B1/ko active Active
- 2009-11-18 CA CA2743976A patent/CA2743976C/fr active Active
- 2009-11-18 DK DK09752380.7T patent/DK2370441T3/da active
- 2009-11-19 US US12/621,547 patent/US8227458B2/en active Active
- 2009-11-25 TW TW098140192A patent/TWI379833B/zh active
- 2009-11-26 AR ARP090104565A patent/AR074409A1/es active IP Right Grant
-
2011
- 2011-03-31 CO CO11039945A patent/CO6341478A2/es active IP Right Grant
- 2011-04-04 IL IL212122A patent/IL212122A/en active IP Right Grant
- 2011-04-28 CR CR20110220A patent/CR20110220A/es unknown
- 2011-05-10 ZA ZA2011/03419A patent/ZA201103419B/en unknown
- 2011-05-10 MA MA33827A patent/MA32781B1/fr unknown
- 2011-05-26 EC EC2011011089A patent/ECSP11011089A/es unknown
-
2012
- 2012-05-15 US US13/471,491 patent/US8461152B2/en active Active
-
2013
- 2013-10-24 CY CY20131100939T patent/CY1115435T1/el unknown
-
2018
- 2018-07-16 AR ARP180101972 patent/AR112338A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32781B1 (fr) | Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine | |
| MA34174B1 (fr) | Hetéroaryl-cyclohexyl-tétraazabenzo[e)azulènes comme antagonistes des récepteurs de la vasopressine v1a | |
| MA34252B1 (fr) | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
| MA34013B1 (fr) | Inhibiteurs du virus de l'hépatite c | |
| MA30289B1 (fr) | Dérivés d'amines | |
| MA34173B1 (fr) | Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes | |
| MA29568B1 (fr) | Composes d'azaindazole et methodes d'utilisation desdits composes | |
| WO2008080844A9 (fr) | Dérivés azaspiro | |
| MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
| MA30778B1 (fr) | Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
| MA33239B1 (fr) | 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires | |
| MA31952B1 (fr) | Pyrrolopyrimidines et pyrrolopyridines | |
| MA31447B1 (fr) | Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1 | |
| MA30406B1 (fr) | Nouveaux composes | |
| TNSN08137A1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
| MA30313B1 (fr) | Amines secondaires en tant qu'inhibiteurs de la renine | |
| MA32798B1 (fr) | Acides naphtylacétiques | |
| MA35874B1 (fr) | Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci | |
| NZ603108A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| MA32688B1 (fr) | Composes n-sulfonamido pyrazolyles polycycliques | |
| MA29554B1 (fr) | Nouveaux derives d'amide d'acide piperidine carboxylique |